PDCO Quote, Financials, Valuation and Earnings

Henry Schein has a net margin of 1.6% compared to Patterson Companies's net margin of 3.12%. Patterson Companies's return on equity of 15.7% beat Henry Schein's return on equity of 6.21%.

Patterson Companies has a consensus price target of $29.68, signalling downside risk potential of -3.84%. On the other hand Henry Schein has an analysts' consensus of $74.83 which suggests that it could grow by 8.14%. Given that Henry Schein has higher upside potential than Patterson Companies, analysts believe Henry Schein is more attractive than Patterson Companies.

Patterson Companies has a beta of 0.896, which suggesting that the stock is 10.422% less volatile than S&P 500. In comparison Henry Schein has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.818%.

Patterson Companies has a quarterly dividend of $0.26 per share corresponding to a yield of 3.37%. Henry Schein offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Patterson Companies pays 52.89% of its earnings as a dividend. Henry Schein pays out -- of its earnings as a dividend. Patterson Companies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Patterson Companies quarterly revenues are $1.7B, which are smaller than Henry Schein quarterly revenues of $3.2B. Patterson Companies's net income of $26.8M is lower than Henry Schein's net income of $99M. Notably, Patterson Companies's price-to-earnings ratio is 18.05x while Henry Schein's PE ratio is 28.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Patterson Companies is 0.42x versus 0.71x for Henry Schein. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of 1.6% compared to Patterson Companies's net margin of -59.9%. Patterson Companies's return on equity of 15.7% beat Standard BioTools's return on equity of -48.03%.

Patterson Companies has a consensus price target of $29.68, signalling downside risk potential of -3.84%. On the other hand Standard BioTools has an analysts' consensus of -- which suggests that it could grow by 76.19%. Given that Standard BioTools has higher upside potential than Patterson Companies, analysts believe Standard BioTools is more attractive than Patterson Companies.

Patterson Companies has a beta of 0.896, which suggesting that the stock is 10.422% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.572, suggesting its more volatile than the S&P 500 by 57.231%.

Patterson Companies has a quarterly dividend of $0.26 per share corresponding to a yield of 3.37%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Patterson Companies pays 52.89% of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend. Patterson Companies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Patterson Companies quarterly revenues are $1.7B, which are larger than Standard BioTools quarterly revenues of $45M. Patterson Companies's net income of $26.8M is higher than Standard BioTools's net income of -$26.9M. Notably, Patterson Companies's price-to-earnings ratio is 18.05x while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Patterson Companies is 0.42x versus 3.14x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of 1.6% compared to Patterson Companies's net margin of -11.09%. Patterson Companies's return on equity of 15.7% beat LENSAR's return on equity of -56.16%.

Patterson Companies has a consensus price target of $29.68, signalling downside risk potential of -3.84%. On the other hand LENSAR has an analysts' consensus of -- which suggests that it could grow by 23.04%. Given that LENSAR has higher upside potential than Patterson Companies, analysts believe LENSAR is more attractive than Patterson Companies.

Patterson Companies has a beta of 0.896, which suggesting that the stock is 10.422% less volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Patterson Companies has a quarterly dividend of $0.26 per share corresponding to a yield of 3.37%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Patterson Companies pays 52.89% of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend. Patterson Companies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Patterson Companies quarterly revenues are $1.7B, which are larger than LENSAR quarterly revenues of $13.5M. Patterson Companies's net income of $26.8M is higher than LENSAR's net income of -$1.5M. Notably, Patterson Companies's price-to-earnings ratio is 18.05x while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Patterson Companies is 0.42x versus 2.09x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.

Zomedica has a net margin of 1.6% compared to Patterson Companies's net margin of -95.71%. Patterson Companies's return on equity of 15.7% beat Zomedica's return on equity of -27.17%.

Patterson Companies has a consensus price target of $29.68, signalling downside risk potential of -3.84%. On the other hand Zomedica has an analysts' consensus of -- which suggests that it could grow by 108.33%. Given that Zomedica has higher upside potential than Patterson Companies, analysts believe Zomedica is more attractive than Patterson Companies.

Patterson Companies has a beta of 0.896, which suggesting that the stock is 10.422% less volatile than S&P 500. In comparison Zomedica has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.877%.

Patterson Companies has a quarterly dividend of $0.26 per share corresponding to a yield of 3.37%. Zomedica offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Patterson Companies pays 52.89% of its earnings as a dividend. Zomedica pays out -- of its earnings as a dividend. Patterson Companies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Patterson Companies quarterly revenues are $1.7B, which are larger than Zomedica quarterly revenues of $7M. Patterson Companies's net income of $26.8M is higher than Zomedica's net income of -$6.7M. Notably, Patterson Companies's price-to-earnings ratio is 18.05x while Zomedica's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Patterson Companies is 0.42x versus 4.40x for Zomedica. Usually stocks with elevated PS ratios are considered overvalued.